Combined Intra-articular Shoulder Injection and Stellate Ganglion Block in Chronic Post-mastectomy Shoulder Pain
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03586154 |
Recruitment Status :
Completed
First Posted : July 13, 2018
Last Update Posted : July 16, 2018
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Background and Purpose: Adhesive capsulitis of the shoulder is commonly found in patients after breast cancer treatment. We aimed to determine the effectiveness of combined shoulder joint intra-articular injection of platelet rich plasma (PRP) with stellate ganglion block (SGB) with ketamine &bupivacaine injection as a new technique for frozen shoulder (FS) management after mastectomy.
Methods: Sixty four patients with chronic post-mastectomy shoulder pain and stiffness were randomly allocated into one of two groups: group A; ultrasound guided SGB (1 ml ketamine in a dose of 0.5mg/kg plus 5ml bupivacaine 0.5% in total volume 10 ml) and group B; ultrasound guided SGB plus posterior approach shoulder injection with PRP. Visual analogue score (VAS) at rest and at shoulder movement, range of motions (ROM) of shoulder and disability of arm, shoulder and hand (DASH) questionnaire were recorded.
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Breast Neoplasms | Combination Product: Platelet rich plasma Drug: ketamine and bupivacaine injection | Phase 4 |

Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 70 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Triple (Participant, Care Provider, Investigator) |
Masking Description: | Investigators were not allowed to know randomization codes and block size until all calculations and measurements had been entered into the database for all patients. All medical caregivers, investigators and patients were blinded to group allocation. One hour before the injection procedure of an enrolled patient, a nurse (not otherwise participating in the study) opened a sealed opaque envelope containing group allocation, and then filled the assigned drug injection for each patient according to the protocol of randomization. |
Primary Purpose: | Treatment |
Official Title: | Combined Platelet Rich Plasma Intra-articular Shoulder Injection and Stellate Ganglion Block. A New Technique for Management of Chronic Post-mastectomy Shoulder Pain Syndrome |
Actual Study Start Date : | August 1, 2017 |
Actual Primary Completion Date : | January 2, 2018 |
Actual Study Completion Date : | April 2, 2018 |

Arm | Intervention/treatment |
---|---|
Group A
patients were subjected to ultrasound guided SGB using 1 ml ketamine in a dose of 0.5mg/kg plus 5ml bupivacaine 0.5% in total volume 10 ml
|
Drug: ketamine and bupivacaine injection
1 ml ketamine in a dose of o.5 ml/kg plus 5ml bupivacaine 0.5% in a total volume 10 ml |
Active Comparator: Group B
patients were subjected to ultrasound guided SGB using 1 ml ketamine in a dose of 0.5mg/kg plus 5ml bupivacaine 0.5% in total volume 10 ml plus posterior approach shoulder injection with PRP.
|
Combination Product: Platelet rich plasma
combined platelet rich plasma and 1 ml ketamine in a dose of o.5 ml/kg plus 5ml bupivacaine 0.5% in a total volume 10 ml
Other Name: PRP Drug: ketamine and bupivacaine injection 1 ml ketamine in a dose of o.5 ml/kg plus 5ml bupivacaine 0.5% in a total volume 10 ml |
- Visual analogue score [ Time Frame: Before injection and 1, 2, 3 months after injection ]Visual analogue score (VAS) was done at rest and at shoulder movement before injection, one, two and three months after injection. VAS was explained to the patients during assessment as 0 equal no pain and 10 equal worst imaginable pain. Shoulder mobility was assessed while the patient was sitting using goniometry.
- Range of motion [ Time Frame: Before injection and one month after injection ]It was measured in degrees in five position (extension, flexion, and abduction, internal and external rotation) before and one month after injection.
- Disability of arm [ Time Frame: Before injection and 1, 2 , 3 months after injection ]shoulder and hand (DASH) questionnaire was done before injection, one, two and three months after injection.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 64 Years (Adult) |
Sexes Eligible for Study: | Female |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- post-mastectomy shoulder pain
- age of 18 to less than 65 years
Exclusion Criteria:
- refusal to participate
- Patients with acute shoulder pain (trauma, acute postsurgical pain)
- secondary adhesive capsulitis (prior surgery or non-surgically induced states of shoulder affection by adhesive capsulitis)
- hypersensitivity to amide local anesthetics
- general contraindications to SGB and cardiac and hepatic, renal or respiratory failure.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03586154
Egypt | |
MansouraU | |
Mansourah, Mansoura, Egypt, 35516 |
Principal Investigator: | Mohamed Tahan, MD | Professor of Anesthesia, Medical Faculty, Mansoura University |
Publications:
Responsible Party: | Nevert Adel, Principal investigator, Mansoura University |
ClinicalTrials.gov Identifier: | NCT03586154 |
Other Study ID Numbers: |
MansouraU Nevert |
First Posted: | July 13, 2018 Key Record Dates |
Last Update Posted: | July 16, 2018 |
Last Verified: | July 2018 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Ketamine; pain; platelet rich plasma; mastectomy; shoulder |
Breast Neoplasms Shoulder Pain Neoplasms by Site Neoplasms Breast Diseases Skin Diseases Arthralgia Joint Diseases Musculoskeletal Diseases Pain Neurologic Manifestations Ketamine Bupivacaine Anesthetics, Local |
Anesthetics Central Nervous System Depressants Physiological Effects of Drugs Sensory System Agents Peripheral Nervous System Agents Analgesics Anesthetics, Dissociative Anesthetics, Intravenous Anesthetics, General Excitatory Amino Acid Antagonists Excitatory Amino Acid Agents Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action |